Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
about
Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin PathwayAmplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancersAntimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivorsExpression profile and prognostic role of sex hormone receptors in gastric cancerDelineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancerHEXIM1 is a critical determinant of the response to tamoxifen.Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fateEndometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.O-GlcNAcylation: A New Cancer Hallmark?Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancerEndobiogeny: a global approach to systems biology (part 2 of 2)Formal modeling and analysis of ER-α associated Biological Regulatory Network in breast cancer.Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of ActionWhat's positive about 'triple-negative' breast cancer?GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progressionAromatase inhibitors: prediction of response and nature of resistance.The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer.Genomic medicine and targeted therapy for solid tumors.Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer.Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy.Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.Estradiol suppresses phosphorylation of ERα serine 167 through upregulation of PP2A in breast cancer cells.ObRb downregulation increases breast cancer cell sensitivity to tamoxifen.
P2860
Q28555056-80CC1B1B-4278-4DCC-81DC-960031CB2095Q28728499-88E077AB-A3B6-4571-A3DF-B72E24E8BF56Q33624886-DA472A4B-14A7-49EE-99C3-FFABA8E998F5Q34496830-B9DA59F9-7010-42EC-8037-0B87C895F1C2Q34747157-5CCC4C55-8DC8-492D-A2F1-A5DD1D3F87A6Q34991926-5CE260EF-B115-47BD-9E7C-DEF82517C3B2Q35106333-1EAE816C-7260-4FE0-B448-C1016F7CA96EQ35178371-B4FAF20E-F806-4EE9-96F0-31D511E4F74CQ35274529-2518F409-B116-41B0-98FA-ECDE6304192BQ35889618-13D45437-550D-44B4-86EE-3D70D21F7D08Q36480044-FA252488-E92F-4DC2-A5B1-46268A0F1BAEQ36575502-0A725B47-480D-4349-B03D-91C502D9A9D7Q36589865-CA82EEE9-DFA7-43C6-8001-ABD043687CF1Q37062403-22C75413-2299-4D15-963F-B9B38AA9A9B0Q37086952-3FD89BF3-B769-42CC-A468-64B3EDAED071Q37174362-1D9ADA5A-57C8-4AED-A442-7E6AD2640A6EQ37323903-1A01EB90-5215-490A-A89B-9CA51F9B70FDQ37359952-1F9A6AE1-B53F-4D24-8E17-8C807B37A92EQ37503537-A907DA5A-4DCA-43C3-9947-5D88004E4E79Q37605859-5F333D57-7767-4046-A6A4-CBD0022EA5F9Q37689922-4A72388B-0E5F-4056-B828-D8AFEC5E6DB9Q37690552-EE42A57B-E657-4393-AAAA-87D796255E9AQ37760220-C10BBA6D-DDFF-4103-9542-E181AA1630ABQ38051247-E91F229A-922B-4448-82D4-42BB16E72C11Q38231825-8AB09CDA-B2FC-4A23-84F9-239A5133F407Q39579728-3560A4D9-17D7-4EB2-8D48-6B86B850D4AEQ41093329-B6A82E18-9AC2-485F-B017-D4AF999201FBQ41619667-12D96E5B-5918-477F-A821-9FF2A843B9EFQ41780559-391490F2-ED95-4983-AEBA-6747AC166EBAQ47394260-D2E6973B-6A6F-4D1D-BE2D-BD903226CCD9Q49195214-B12E73A5-5180-4CC1-9E99-985E030F9808Q53555843-0C31A562-87E3-4647-BD0A-9DB14E01E17B
P2860
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Rational management of endocri ...... ptions, and future directions.
@en
Rational management of endocri ...... ptions, and future directions.
@nl
type
label
Rational management of endocri ...... ptions, and future directions.
@en
Rational management of endocri ...... ptions, and future directions.
@nl
prefLabel
Rational management of endocri ...... ptions, and future directions.
@en
Rational management of endocri ...... ptions, and future directions.
@nl
P2860
P356
P1433
P1476
Rational management of endocri ...... options, and future directions
@en
P2093
Sara A Hurvitz
P2860
P304
P356
10.1002/CNCR.23875
P407
P577
2008-11-01T00:00:00Z